Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

IntroductionRelapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) has poor clinical outcomes when treated with conventional salvage chemotherapy. Monotherapy using zanubrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, has achieved modest antitumor effect in R/R DLBCL. Here w...

Full description

Bibliographic Details
Main Authors: Xianggui Yuan, Xian Li, Yurong Huang, Xueli Jin, Hui Liu, Aiqi Zhao, Weiping Zhang, Wenbin Qian, Yun Liang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
relapsed or refractory diffuse large B-cell lymphoma
zanubrutinib
Bruton’s tyrosine kinase inhibitor
combination chemotherapy
TP53
chimeric antigen receptor T-cell (CAR-T)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1015081/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1015081/full

Similar Items